AUSTRALIA-CHINA BIOTECH Five Reasons to Attend: INVEST ...€¦ · Benefit from expert analysis on...
2
Five Reasons to Attend: Benefit from expert analysis on bio-tech investment an partnering from: Confirmed Speakers: Invited Speakers: Who Should Attend: Scan the code and join ourWechat group for more information: Time： 15-16 March, 2018 Address： KPMG SHANGHAI 9th Floor, Tower I, Plaza 66 1266 Nanjing West Road Shanghai 200040 China Network with Australian biotech CEOs,Chinese pharma executives and life science investors Learn the secrets of successful partnerships and investments in China Discuss financing, capital raising and exit strategies with industry experts Explore actual life science investment and partnership opportunities Engage in one-on-one meetings with over 200 participants Glenn Cross Chief Executive Officer AusBiotech Darren Ji Venture Partner Lilly Asia Ventures David Burton Founder, Chairman, CEO Compumedics Limited Russell Bateman Chief Operating Officer CPIC Allianz Health Insurance Ben Ni Operating Partner iBridge Capital Cyndi Zhai Founder and General Manager Joyin Life Science Incubators Jimmy Zhang Director CI Investment Group David Bennett Counsellor (Intellectual Property) Australian Embassy Bejing Li Fern Woo China Life Sciences Head KPMG China Glenn Cross, Chief Executive Officer, AusBiotech; Darren Ji, Venture Partner, Lilly Asia Ventures; David Burton, Founder, Chairman, CEO, Compumedics Limited; Russell Bateman, Chief Operating Officer, CPIC Allianz Health Insurance; Ben Ni, Operating Partner, iBridge Capital; Cyndi Zhai, Founder and General Manager, Joyin Life Science Incubators; David Bennett, Counsellor (Intellectual Property), Australian Embassy Beijing; Li Fern Woo, China Life Sciences Head, KPMG China; Jimmy Zhang, Director, CI Investment Group; Sue MacLeman, Managing Director and Chief Executive Officer, MTPConnect (MedTech and Pharma Growth Centre-MTP-IIGC Ltd.); Daniel Zhan, Australian Landing Pad Manager, Australian Trade and Investment Commission Auskin Zhou, Vice president, SDIC Fund Management; Dr. Tong Zhang, Senior Director R&D, Guangzhou Wondefo Biotech; Irene Zhang, Senior Investment Director, Fosun Pharma; Jie Zhang, Director, WuXi Healthcare Ventures; Jonathan J.Wang, Senior Managing Director, OrbiMed Healthcare Fund Management; Marietta Wu, Chief Operating Officer, ZAI Laboratory; Sebastien Gaudin, CEO & Co-founder, The CareVoice; Tom Folinsbee, Director, Corporate Development, 3SBio Inc.; Wayne Li, Partner, Morningside Ventures Life Science investors Biotech/ medtech CEOs Pharma executives CMO/CROs Sponsors and Supporters: Meet over 20 Australian life-science and medical device companies, including: To Register Visit: AUSTRALIA-CHINA BIOTECH INVEST & PARTNERING http://www.ausbiotechinvestment.com.au/ or https://ausbiotech.eventsair.com/asian- investment-series-2018/shanghaiinvestor/ Site/Register Email: [email protected] / [email protected]
Transcript of AUSTRALIA-CHINA BIOTECH Five Reasons to Attend: INVEST ...€¦ · Benefit from expert analysis on...
Five Reasons to Attend:
Benefit from expert analysis on bio-tech investment anpartnering from:
Confirmed Speakers:
Invited Speakers:
Who Should Attend:
Scan the code and join ourWechat group for more information:
Time： 15-16 March, 2018
Address： KPMG SHANGHAI
9th Floor, Tower I, Plaza 66
1266 Nanjing West Road
Shanghai 200040 China
Network with Australian biotech CEOs,Chinese pharma executives and life science investors Learn the secrets of successful partnerships and investments in China
Discuss financing, capital raising and exit strategies with industry experts
Explore actual life science investment and partnership opportunities
Engage in one-on-one meetings with over 200 participants
Glenn CrossChief Executive Officer
AusBiotech
Darren JiVenture Partner
Lilly Asia Ventures
David BurtonFounder, Chairman, CEO
Compumedics Limited
Russell BatemanChief Operating Officer
CPIC Allianz Health Insurance
Ben NiOperating Partner
iBridge Capital
Cyndi ZhaiFounder and General ManagerJoyin Life Science Incubators
Jimmy ZhangDirector
CI Investment Group
David BennettCounsellor (Intellectual Property)
Australian Embassy Bejing
Li Fern WooChina Life Sciences Head
KPMG China
Glenn Cross, Chief Executive Officer, AusBiotech; Darren Ji, Venture Partner, Lilly Asia Ventures; David Burton, Founder, Chairman,
CEO, Compumedics Limited; Russell Bateman, Chief Operating Officer, CPIC Allianz Health Insurance; Ben Ni, Operating Partner,
iBridge Capital; Cyndi Zhai, Founder and General Manager, Joyin Life Science Incubators; David Bennett, Counsellor (Intellectual
Property), Australian Embassy Beijing; Li Fern Woo, China Life Sciences Head, KPMG China; Jimmy Zhang, Director, CI Investment
Group; Sue MacLeman, Managing Director and Chief Executive Officer, MTPConnect (MedTech and Pharma Growth Centre-MTP-IIGC
Ltd.); Daniel Zhan, Australian Landing Pad Manager, Australian Trade and Investment Commission
Auskin Zhou, Vice president, SDIC Fund Management; Dr. Tong Zhang, Senior Director R&D,
Guangzhou Wondefo Biotech; Irene Zhang, Senior Investment Director, Fosun Pharma;
Jie Zhang, Director, WuXi Healthcare Ventures; Jonathan J.Wang, Senior Managing Director, OrbiMed Healthcare Fund
Management; Marietta Wu, Chief Operating Officer, ZAI Laboratory; Sebastien Gaudin, CEO & Co-founder, The CareVoice;
Tom Folinsbee, Director, Corporate Development, 3SBio Inc.; Wayne Li, Partner, Morningside Ventures
Life Science investors
Biotech/medtech CEOs
Pharma executives
CMO/CROs
Sponsors and Supporters:Meet over 20 Australian life-science and medical device companies,including:
To Register Visit:
AUSTRALIA-CHINA BIOTECH
INVEST & PARTNERING
http://www.ausbiotechinvestment.com.au/or https://ausbiotech.eventsair.com/asian-investment-series-2018/shanghaiinvestor/Site/Register
Email: [email protected] / [email protected]
中澳生物科技投资与合作大会
五大与会理由：
参会收获演讲嘉宾在生物科技投资与合作方面的专业分析：
与会演讲嘉宾：
受邀演讲嘉宾：
参会人群：
请扫码关注获取更多会议信息：
日期： 2018年3月15日-16日
地址： KPMG上海办公室上海市静安区南京西路1266号恒隆广场1号楼9层
与澳大利亚生物科技公司总裁、中国药企高管以及生命科学方向投资方进行接洽
了解在中国成功获得融资与合作的秘诀
与行业专家探讨金融融资和退出战略；
探索生命科学领域投资与合作的真实机会
与200多名与会人员进行一对一沟通
Glenn Cross首席执行官
澳大利亚生物科技组织
纪晓辉投资合伙人
礼来亚洲基金
David Burton创始人、董事长兼首席执行官
Compumedics Limited
Russell Bateman首席运营官
太保安联健康保险股份有限公司
倪彬辉运营合伙人
iBridge Capital
翟靖波创始人兼总经理
衍禧堂医疗孵化器
Jimmy Zhang总监
CI Investment Group
David Bennett知识产权参赞
澳大利亚驻北京大使馆
胡丽芬生命科学中国区主管
毕马威中国
Glenn Cross, 首席执行官, 澳大利亚生物科技组织; 纪晓辉, 投资合伙人, 礼来亚洲基金; David Burton, 创始人, 董事长兼首席
执行官, Compumedics Limited; 陆森, 副总经理兼运营总监, 太保安联健康保险股份有限公司; 倪彬辉, 运营合伙人, iBridge
Capital; 翟靖波, 创始人兼总经理, 衍禧堂医疗孵化器; David Bennett, 知识产权参赞, 澳大利亚驻北京大使馆; 胡丽芬, 生命科
学中国区主管, 毕马威中国; Jimmy Zhang, 总监, CI Investment Group; Sue MacLeman, 总经理兼首席执行官, MTPConnect
(MedTech and Pharma Growth Centre-MTP-IIGC Ltd.); Daniel Zhan, 创客登陆计划总监, 澳大利亚贸易投资委员会
周乃俊, 副总裁, 国投创新投资管理有限公司; Dr. Tong Zhang, 高级经理, 万孚生物技术股份有限公司;
Irene Zhang, 高级投资总监, 复兴医药; Jie Zhang, 总监, 毓承资本; 王健, 资深董事总经理, 奥博资本; 巫荟, 首席运营官, 再鼎
医药; Sebastien Gaudin, 联合创始人兼首席执行官, 康语商务咨询(上海)有限公司; Tom Folinsbee, 企业发展及投资部总监,
三生制药; 李文宝, 投资经理, 晨兴科技
生命科学领域投资者
生物科技/医疗技术公司高管
制药公司高管 首席市场官/首席风控官
特此感谢以下所有公司和机构对此次大会的支持：参会接洽25余家澳大利亚生命科学和医疗设备公司高管，包括：
参会注册请访问：http://www.ausbiotechinvestment.com.au/或https://ausbiotech.eventsair.com/asian-investment-series-2018/shanghaiinvestor/Site/Register
